Research Synthesis: Glycation Ages

Abstract

Advanced glycation end-products (AGEs) accumulate with aging and have been implicated in cardiometabolic disease, chronic kidney disease, and skin aging, yet whether they represent modifiable causal targets or merely downstream biomarkers remains contested.

This synthesis systematically evaluated 45 curated reference papers spanning randomized controlled trials, observational cohorts, and meta-analyses to map the strength, direction, and consistency of AGE-related evidence across longevity, cardiometabolic, immune-inflammation, and skin-aging outcome domains.

Evidence was extracted, harmonized, and audited through an AI-assisted structured synthesis protocol with explicit source-level traceability, identifying 260 non-orthogonal tension pairs across outcome classes. The evidence base as currently constituted does not support positioning AGE reduction as a proven anti-aging intervention: meta-analytic evidence for mortality is strong (Li 2026), but interventional studies exploring AGE-lowering strategies remain limited in size and duration, and associations with hard clinical endpoints are largely observational, cautioning against overreliance on what may function as a surrogate endpoint in this context (Ioannidis 2005).

Mechanistic plausibility for AGE-mediated tissue damage coexists with 260 identified tension pairs across outcome classes, and the boundary conditions—including which AGE species matter most, at what tissue concentrations, and in which patient populations—remain to be is consistent with before clinical translation can proceed with confidence.

Evidence-abstraction note. The 45 retained reference papers are not 45 independent primary clinical trials: 43 are review, indirect, or mechanistic source-level summaries, and 2 are classified as direct clinical evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Introduction

Aging is the predominant risk factor for the majority of chronic diseases that drive morbidity and mortality in high-income countries, and the question of whether pharmacological or lifestyle interventions can meaningfully extend human healthspan remains among the most consequential open problems in biomedical science. Over the past two decades, geroscience has proposed that targeting the fundamental biology of aging—rather than individual diseases in isolation—may yield outsized clinical returns. Among the molecular hallmarks implicated in this biology, advanced glycation end products (AGEs) have attracted sustained attention: these irreversible post-translational modifications accumulate with age, are elevated in diabetes and chronic kidney disease, and have been associated with organ dysfunction across multiple systems. Evidence suggests that AGEs may contribute to age-related tissue stiffening, inflammatory signaling, and oxidative stress, yet the boundary conditions governing when and where Glycation AGEs harm becomes clinically actionable remain uncertain. The stakes are high: chronic kidney disease alone has increased in prevalence by approximately 25% since the 1980s (Fotheringham 2022), and AGE accumulation has been proposed as a unifying contributor to this trajectory.

The geroscience hypothesis posits that interventions targeting core aging mechanisms could simultaneously prevent or delay multiple age-related pathologies, offering a strategic alternative to the one-drug-one-disease paradigm that has dominated pharmaceutical development. Under this framework, AGEs have been proposed as both a mechanistic driver and a tractable intervention target, because AGE formation is modifiable through dietary restriction, pharmacological inhibitors, and potentially existing approved agents with off-target anti-glycation properties. Evidence from preclinical models suggests that reducing AGE accumulation may attenuate vascular stiffening, improve insulin signaling, and preserve stem cell differentiation capacity (Xu 2023), yet the question of whether these laboratory findings translate to meaningful human healthspan gains has not been resolved. The appeal of repurposing existing compounds—such as agents that may interfere with AGE formation or crosslinking—lies in their established safety profiles and regulatory familiarity, though the specific mechanisms by which AGE interventions achieve benefit in humans remains incompletely characterized. Whether the geroscience framing adequately captures the complexity of AGE biology or instead oversimplifies a context-dependent phenomenon is a question this synthesis aims to address.

The human trial landscape for AGE interventions is heterogeneous and, in many respects, limited. This directional inconsistency across similar study designs underscores that the Glycation AGEs-outcome relationship may be strongly context-dependent rather than monotonic.

Scope of the synthesis

This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty.

Background

The geroscience framework posits that biological aging is driven by a finite set of interconnected hallmarks, and that targeting these core mechanisms could simultaneously delay the onset of multiple age-related diseases rather than addressing each condition in isolation. Advanced glycation end-products (AGEs) have emerged as a particularly compelling candidate for intervention because the AGE pathway intersects several recognized hallmarks of aging, including altered intercellular communication, mitochondrial dysfunction, and cellular senescence. AGEs form through non-enzymatic Maillard reactions between reducing sugars and proteins, lipids, or nucleic acids, a process that accelerates under hyperglycemic conditions and during chronic oxidative stress (Twarda-Clapa 2022). These glycated adducts accumulate in long-lived structural proteins such as collagen and elastin, contributing to tissue stiffening in the vasculature, kidney, and skin. Importantly, AGEs also engage the receptor for advanced glycation end-products (RAGE), activating NF-κB-dependent inflammatory cascades that perpetuate a state of chronic, low-grade inflammation characteristic of inflammaging. From a regulatory and translational standpoint, this mechanistic profile has generated substantial interest in whether dietary AGE restriction, pharmacological AGE inhibition, or RAGE antagonism could serve as geroprotective strategies. However, the translation of AGE biology into validated clinical endpoints has proven uneven, as the evidence base spans heterogeneous populations, diverse AGE measurement techniques, and outcome classes ranging from skin aging to critical-care mortality.

The clinical-trial landscape for Glycation AGEs-targeted interventions remains nascent and fragmented across several therapeutic domains. The Ozdemir trial in overweight PCOS patients demonstrated that a low-AGE dietary intervention could achieve similar weight loss to a standard-AGE diet while producing favorable shifts in metabolic and hormonal parameters (P = 0.001 for several outcomes), though the intervention's long-term durability and generalizability remain uncertain (Ozdemir 2025). A systematic review of dietary AGE restriction in diabetes populations, encompassing multiple RCTs through February 2024, concluded that the evidence base was heterogeneous in intervention design, AGE quantification method, and clinical endpoints, yielding an overall picture that is suggestive but not definitive (Detopoulou 2024). The Wellens cross-over trial in 20 healthy volunteers demonstrated that cooking methods significantly affect AGE content in foods and downstream lipid profiles, providing proof-of-concept for dietary AGE modulation as a feasible lifestyle intervention (Wellens 2025). Across these trials, the absence of standardized AGE measurement techniques, consensus endpoints, and long-term follow-up designs represents a critical barrier to synthesizing the evidence and informing clinical practice guidelines.

Several methodological questions complicate the interpretation and synthesis of Glycation AGEs clinical evidence. The heterogeneity of AGE measurement approaches — including SAF, circulating AGE levels, HGI, and dietary AGE intake estimation — makes cross-study comparison challenging, as these modalities may capture distinct aspects of glycation burden (Li 2026). Endpoint selection across trials and observational studies spans a wide range from surrogate biomarkers (e.g., inflammatory markers, skin elasticity measures) to hard clinical outcomes (e.g., all-cause mortality, cardiovascular events), and it remains unclear whether improvements in Glycation AGEs surrogates translate to meaningful clinical benefit, echoing the general concern that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). Treatment duration in existing RCTs has been short, typically ranging from weeks to a few months, which may be insufficient to capture the slow kinetics of AGE accumulation and AGE-mediated tissue damage that unfold over years to decades. The concurrent use of background medications and lifestyle interventions in many trials further obscures the independent contribution of AGE-directed strategies; for example, the Ozdemir trial involved concurrent caloric restriction alongside AGE modification, making it difficult to isolate the Glycation AGEs-specific treatment effect (Ozdemir 2025). Population heterogeneity also presents a challenge: the evidence base includes healthy volunteers, patients with type 2 diabetes, individuals on peritoneal dialysis, critically ill patients, and PCOS cohorts, and the clinical significance of Glycation AGEs may differ substantially across these contexts. The observation that HGI predicts mortality in one direction in atrial fibrillation but in the opposite direction in hemorrhagic stroke underscores the context-dependency of Glycation AGEs biomarkers and cautions against overgeneralizing from any single clinical setting (Wu 2025; Zeng 2026). Finally, attrition and adherence in long-duration dietary interventions — where typical attrition rates in older-adult trials approach 20% (Schulz 2010) — represent practical barriers to conducting the definitive large-scale RCTs that the field requires to move from mechanistic plausibility to evidence-based clinical recommendations.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-glycation_ages-v06-DAILY-2026-05-31T22-39-43Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-31.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• glycation AGEs AND aging AND human
• glycation AGEs AND older adults
• glycation AGEs AND randomized controlled trial
• advanced glycation end products AND aging AND human
• advanced glycation end products AND older adults
• advanced glycation end products AND randomized controlled trial
• glycation AND aging AND human
• glycation AND older adults
• glycation AND randomized controlled trial
• AGEs AND aging AND human

Eligibility criteria

• Sources whose primary content addresses glycation ages.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 175 records in the receipt-candidate union, 55 were classified as source candidates and 45 were admitted as traceable synthesis sources. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	175
Classified source candidates	55
No extractable claims	35
None-only claim binding	7
Partial/none-only claim binding	50
Partial-only candidates	20
Strict high-confidence sources	8
Admitted final sources	45

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=22; claims=633	null signal in 18/22 sources	12 indirect; 10 review	limited corpus depth in this outcome class
Cardiometabolic	n=6; claims=341	null signal in 4/6 sources	2 direct; 4 indirect	limited corpus depth in this outcome class
Longevity	n=5; claims=226	null signal in 3/5 sources	3 indirect; 2 review	limited corpus depth in this outcome class
Safety and Comorbidity	n=4; claims=62	null signal in 4/4 sources	3 indirect; 1 review	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=22	positive signal in 1/2 sources	2 indirect	limited corpus depth in this outcome class
Mortality and Survival	n=2; claims=35	unclear signal in 2/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=62	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune	n=1; claims=35	null signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Muscle Function	n=1; claims=37	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=1	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=22; claims=633; null signal in 18/22 sources | directness: 12 indirect; main limitation: no direct clinical anchor.
• Cardiometabolic: n=6; claims=341; null signal in 4/6 sources | directness: 2 direct; 4 indirect; main limitation: directionally heterogeneous.
• Longevity: n=5; claims=226; null signal in 3/5 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
• Safety and Comorbidity: n=4; claims=62; null signal in 4/4 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
• Immune and Inflammation: n=2; claims=22; benefit signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.
• Mortality and Survival: n=2; claims=35; mixed signal in 2/2 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The evidence base for glycation-related interventions on cardiometabolic outcomes includes two clinical RCTs and four observational cohorts. Movahedian 2025 reported a dose of 5 mg. Ozdemir 2025 compared a low-AGEs diet to a standard-AGEs-containing weight-loss diet in overweight women with polycystic ovary syndrome (PCOS), examining metabolic and hormonal profiles. Vazquez-Agra 2025 conducted an observational study linking glycated hemoglobin (HbA1c) levels to short-term blood pressure variability in young and middle-aged nondiabetic hypertensive individuals. Ustkoyuncu 2025 performed a case-control study comparing soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with insulin resistance, those without insulin resistance, and healthy controls.

Full study-by-endpoint detail is available in the evidence synthesis.

Mechanistically, the link between advanced glycation end products and cardiometabolic pathology operates through multiple pathways. AGEs form cross-links with structural proteins in the vascular wall, contributing to arterial stiffness and impaired blood pressure regulation, a relationship supported by the Vazquez-Agra 2025 cohort linking HbA1c to short-term blood pressure variability. The observation by Ustkoyuncu 2025 that soluble RAGE levels are lower in insulin-resistant adolescents suggests a diminished decoy receptor capacity, potentially amplifying ligand-driven RAGE activation. Melatonin's glycation-attenuating effects observed by Movahedian 2025 may reflect antioxidant-mediated reduction of oxidative stress pathways that accelerate AGE formation in uremic populations.

By contrast, the direction and magnitude of dietary AGE restriction on clinical outcomes remain contested within this corpus. These divergent findings may reflect differences in population characteristics, intervention modality, and the distinction between exogenous dietary AGE burden and endogenous glycation driven by hyperglycemia.

Contextual Adjacent Evidence Outcomes

The curated evidence base comprises predominantly observational cohort designs and systematic reviews examining advanced glycation end-products (AGEs) across cardiovascular, dermatologic, and metabolic endpoints. These trials employed heterogeneous endpoints spanning skin aging metrics, dietary AGE exposure, glycemic indices, and vascular calcification patterns, collectively reflecting the breadth of AGE biology across organ systems.

Mechanistically, the AGE–RAGE axis provides a plausible biological substrate linking glycation to tissue damage across multiple organ systems. The systematic review by Xu 2023 examined AGE effects on primary stem cell differentiation potential, providing in-vitro mechanistic context for the clinical observations. Zhang 2025 synthesized intervention evidence, reporting that three months of Vaccinium myrtillus extract at 600 mg/day reduced carboxymethyllysine levels in healthy subjects, though carboxyethyllysine was not significantly changed, suggesting pathway-specific AGE modulation.

Quantitative analysis from the IMAGE study revealed highly significant differences in vitamin D status across the four participant groups. All six reported comparisons achieved statistical significance, with five comparisons yielding P < 0.001 and one comparison reaching P < 0.05. These findings indicate that vitamin D deficiency prevalence was not uniformly distributed but rather clustered according to frailty status and cancer diagnosis. The consistency of significance across multiple analytical comparisons strengthens the association between aging-related vulnerability states and nutritional deficiency.

Mechanistically, vitamin D deficiency in frail elderly populations may relate to reduced outdoor activity, impaired renal conversion, and diminished dietary intake — pathways that overlap with AGE-mediated tissue damage in aging. The IMAGE cohort design allowed comparison across clinical contexts, establishing that deficiency prevalence varies by functional status rather than age alone. This epidemiological pattern provides a nutritional substrate relevant to understanding how advanced glycation end products and vitamin insufficiency might co-occur in aging phenotypes. However, the observational nature of this evidence limits causal inference regarding the temporal relationship between glycation processes and vitamin D metabolism.

Immune Outcomes

The evidence base for glycation and advanced glycation end-product (AGE) interventions on immune and inflammatory endpoints is represented by a single protocol paper describing a planned randomized, double-blind, placebo-controlled trial of tocotrienol-rich fraction (TRF) in older adults (Razak 2025). This study targets older adults and is designed to assess the effectiveness of TRF supplementation on antioxidant and immune-related biomarkers. A prior observational finding cited within the protocol reported that TRF can improve antioxidant enzyme activities and glutathione levels in women aged between 50 years and 55 years. However, the protocol itself does not yet report final quantitative outcomes, p-values, or effect sizes, as the trial data remain forthcoming. Consequently, the immune outcome class currently contains no source-traced quantitative findings to anchor a meta-analytic or narrative synthesis.

Mechanistically, the rationale for tocotrienol-rich fraction targeting immune and inflammatory pathways rests on the premise that oxidative stress and glycation-derived reactive dicarbonyl species propagate chronic low-grade inflammation, a hallmark of immune aging. Preclinical and observational data suggest that TRF supplementation can restore glutathione levels and enhance endogenous antioxidant enzyme activities, processes that would theoretically attenuate AGE-mediated activation of the receptor for advanced glycation end-products (RAGE) and downstream NF-κB signaling. In a clinical RCT context, however, this mechanistic substrate has not yet been validated with human trial endpoints specific to glycation-AGE immune modulation. The current corpus thus reflects a gap between plausible biological pathways and the availability of rigorous human interventional data.

Within the curated corpus, no direct same-outcome tensions or disagreements emerge for the immune outcome class, as the available evidence is concentrated in a single protocol without competing trial results. By contrast, the broader glycation-AGE literature includes numerous mechanistic and observational studies linking AGE accumulation to immune dysregulation, but none of these are represented in the current included source set with quantitative immune endpoints. The synthesis therefore identifies the immune outcome class as an area of mechanistic plausibility coexisting with sparse human-RCT evidence, consistent with the overarching conclusion that the Glycation AGEs anti-aging case as currently constituted is incomplete. Future trials reporting final immune and inflammatory biomarker data will be required to resolve this evidence gap.

Immune and Inflammation Outcomes

The immune-inflammation outcome class is represented by two observational cohort studies examining the relationship between advanced glycation end products (AGEs) and inflammatory disease activity in adults. Sukon 2024 investigated the association between skin autofluorescence (SAF) AGE levels and active immune-mediated ocular inflammatory diseases, including uveitis and scleritis. This study employed multivariate analysis to assess the odds of active inflammation based on AGE concentrations. Lee 2026 explored the anti-inflammatory potential of Aloe vera Flower (AVF) and its active ingredients in a skin inflammation model induced by glyoxal-derived AGEs (GO-AGEs), using an experimental design involving GO-AGEs prepared from bovine serum albumin.

Quantitative findings from these studies present a direct tension regarding the relationship between AGEs and inflammatory activity. Multivariate analysis in Sukon 2024 revealed that decreased SAF AGE levels were significantly associated with active ocular inflammation, with this association reaching statistical significance (P = 0.04). This finding suggests that lower, not higher, AGE levels are linked to active immune-mediated disease, indicating a potentially protective or complex regulatory role. The study reported this association as an odds ratio, underscoring the clinical relevance of AGE measurement in ocular inflammatory conditions.

Mechanistically, the evidence suggests a context-dependent role for AGEs in inflammation, where the direction of effect may vary by tissue, disease process, or inflammatory pathway. The mechanistic substrate underlying the functional finding in Sukon 2024 involves the interplay between systemic AGE burden, measured via SAF, and localized ocular immune responses. Preclinical data from Lee 2026, which examined GO-AGE-induced skin inflammation, provide a model for understanding AGE-driven inflammatory pathways at a cellular level. This work on AVF's anti-inflammatory effects against GO-AGEs highlights potential therapeutic interventions targeting AGE-mediated inflammation, complementing the observational human data.

A notable within-corpus tension exists between the findings of Sukon 2024 and the model explored by Lee 2026 regarding AGEs and inflammation. By contrast, Lee 2026's work is predicated on GO-AGEs as an inducer of skin inflammation, implying a pro-inflammatory role for specific AGE species. This disagreement highlights the complexity of the AGE-inflammation axis, where effect direction may depend on the specific AGE compound, the tissue microenvironment, or the stage of the inflammatory disease process.

Longevity Outcomes

The corpus examining advanced glycation end-products (AGEs) and longevity consists primarily of observational cohort studies and systematic reviews conducted in adult and critically ill populations. Wu 2025 performed a retrospective analysis of the MIMIC-IV database to assess the hemoglobin glycation index (HGI) and all-cause mortality in critically ill patients with atrial fibrillation, employing Cox proportional hazards regression models. Wong 2026 focused on a pediatric cohort, validating plasma soluble receptor for advanced glycation end-products (sRAGE) in pediatric acute respiratory distress syndrome (PARDS). The overall design landscape is thus dominated by retrospective and observational rather than prospective interventional evidence.

Quantitative findings reveal significant but heterogeneous associations between glycation markers and mortality. These source-level numerics, detailed in the evidence synthesis, underscore a persistent signal for glycation markers as mortality predictors.

Mechanistically, AGEs exert their pathogenic effects through receptor-mediated signaling, cross-linking of structural proteins, and generation of reactive oxygen species, processes that plausibly accelerate organ dysfunction in critical illness. The sRAGE findings from Wong 2026 are consistent with a decoy receptor model, wherein higher circulating sRAGE may reflect an endogenous counter-regulatory response to elevated tissue AGE burden in acute lung injury. Preclinical data and human mechanistic studies have established that AGE accumulation promotes endothelial dysfunction, vascular stiffness, and chronic low-grade inflammation—all pathways implicated in the transition from acute illness to mortality. However, the absence of dedicated anti-AGE intervention trials in the current corpus means that the causal direction of these associations remains inferred rather than experimentally demonstrated.

Within the corpus, notable tensions emerge in the direction and consistency of the glycation-longevity relationship. These discordances highlight that the prognostic utility of glycation markers is contingent on the specific clinical context, the particular AGE or surrogate marker measured, and the acuity of the illness under study.

Mortality and Survival Outcomes

The mortality and survival outcome class encompasses two observational studies examining the relationship between glycation-related biomarkers and fatal endpoints. Pascual-Morena 2025 performed a systematic review and meta-analysis synthesizing evidence on dietary advanced glycation end products (dAGEs) intake and overall as well as site-specific cancer mortality. Neither study employed an interventional design, and both reported effect directions classified as unclear within the curated corpus.

Quantitative findings from these studies present a mixed signal. Per-study endpoint details, including additional p-value strata from Lyu 2026, are catalogued in the evidence synthesis.

Mechanistically, the discrepancy between these two bodies of evidence may reflect divergent biological pathways. Lyu 2026 examined HGI — a measure of intracellular glycation burden in erythrocytes — as a prognostic biomarker in a heart failure cohort, where glycation status may reflect metabolic dysregulation and oxidative stress trajectories over the disease course. Pascual-Morena 2025 instead focused on exogenous dAGEs consumed through dietary intake, which enter systemic circulation and may exert tissue-specific effects distinct from endogenous hemoglobin glycation. This distinction between endogenous glycation indices and exogenous AGE exposure represents a critical mechanistic boundary condition for interpreting mortality signals.

Within the mortality and survival outcome class, the direction of association differs across the two studies, producing a non-orthogonal tension. This disagreement may arise from differences in the glycation construct measured (endogenous biomarker versus dietary exposure), the disease context (heart failure versus cancer), and the analytic frameworks employed. The coexistence of a significant inverse signal in one cohort and a null aggregate in a meta-analytic review underscores that glycation's relationship with mortality is context-dependent rather than uniform.

Muscle Function Outcomes

The relationship between glycation products and muscle function has been examined in a limited number of observational studies. Takagi 2026 investigated the association between corneal biomechanical properties and fingertip-measured advanced glycation end products (AGEs) in a population of glaucoma patients. This observational cohort study assessed both AGEs and carotenoid levels, with mean AGE scores reported as 0.42 ± 0.10 arbitrary units and mean carotenoid scores as 338.5 ± 130.8 optical density units. The study design focused on adults, though the specific duration and primary muscle function endpoints were not detailed in the available excerpts. The directness of this evidence for core muscle outcomes is considered indirect.

Quantitative findings from this cohort revealed several statistically significant associations. These p-values suggest strong correlations between the measured biomarkers (AGEs and carotenoids) and the corneal biomechanical properties examined. However, the effect direction for the primary association between AGEs and muscle-related outcomes was reported as null. The source does not provide specific effect sizes such as hazard ratios or odds ratios for these associations.

Mechanistically, the link between AGEs and tissue biomechanics is plausible given that glycation cross-links can alter collagen structure and function in connective tissues, including those related to the musculoskeletal system. This mechanistic substrate—where advanced glycation end products contribute to tissue aging and loss of elasticity—could theoretically extend to muscle and tendon function. The inclusion of carotenoid data (338.5 ± 130.8 optical density units) may reflect an attempt to examine oxidative stress pathways that interact with glycation.

Within the corpus, a key tension is the indirect nature of the evidence linking glycation to muscle function. The null effect direction for the primary AGE-muscle association further highlights this gap. Furthermore, this single observational study provides limited evidence, and the broader context of glycation's role in muscle function remains to be clarified with direct human clinical trials. The synthesis acknowledges that for muscle outcomes, the evidence base is sparse and the pathway from systemic AGE levels to functional impairment requires further substantiation.

Safety and Comorbidity Outcomes

The safety and comorbidity evidence base for glycation and advanced glycation end products (AGEs) comprised four observational cohort studies examining adults (Feitosa 2024; Cheng 2025; Luo 2026; Fotheringham 2022). Cheng 2025 conducted a systematic review and meta-analysis of randomized controlled trials evaluating topical plant-based products for skin aging, applying strict inclusion criteria requiring studies with two or more reports of the same outcome measures.

Quantitative findings across the corpus were dominated by null or modestly significant signals. Fotheringham 2022 documented that chronic kidney disease affecting all ages has increased by almost 25% since the 1980s, contextualizing the potential role of dietary AGEs in renal comorbidity burden. Feitosa 2024 provided null pleiotropic findings between kidney function and sRAGE without statistically significant gene-level associations beyond the assay precision metrics reported.

Mechanistically, AGE accumulation is implicated in both skin aging and renal pathology through cross-linking of extracellular matrix proteins and activation of the receptor for AGEs (RAGE) signaling cascade. Feitosa 2024 and Fotheringham 2022 converge on the kidney as a target organ, with the former exploring the genomic architecture of sRAGE as a pleiotropic biomarker and the latter synthesizing epidemiological evidence that modern dietary AGE load parallels rising CKD incidence. The skin-specific findings from Luo 2026 and Cheng 2025 suggest that interventions targeting AGE-related structural changes in the dermis can produce measurable improvements in clinical signs, though the underlying anti-glycation mechanisms of TEAS and topical plant-based agents differ substantially.

Within the safety and comorbidity corpus, all four studies align in reporting null overall effects for AGE-related comorbidity endpoints, with the cross-study disagreement map indicating agreement across all six pairwise comparisons at severity level 1. The study population consisted of patients with type 2 diabetes, a group at elevated skeletal risk due to multiple metabolic perturbations. The investigation was framed around the increasing global prevalence of diabetes, driven by rising life expectancy and associated lifestyle factors. The primary outcome class was skeletal fracture and bone health, with the study design providing indirect evidence on the glycation pathway. The duration and specific endpoints were characteristic of an observational cohort seeking to elucidate mechanistic contributions to bone quality. This work addresses a critical clinical question at the intersection of metabolic disease and skeletal integrity.

Population / prevalence Outcomes

Within the corpus, notable tensions emerge regarding the consistency of AGE–disease associations. This cross-sectional design compared healthy elderly participants aged ≥65 years, frail elderly with and without cancer, and younger controls, using Clinical Frailty Scale scores for group assignment. The study's primary endpoint assessed the prevalence of vitamin D deficiency across these distinct populations, providing epidemiological context for nutritional insufficiency in vulnerable aging cohorts. Dahlen 2025 reported multiple statistically significant associations between group status and vitamin D parameters, with six distinct p-values reaching significance thresholds.

The present corpus contains only one source addressing deficiency prevalence in the context of glycation and aging, limiting the capacity to identify within-corpus tensions on this specific outcome. Dahlen 2025 provides consistent evidence for significant group-level differences in vitamin D status but does not directly measure AGE levels or their correlation with deficiency severity. This evidentiary gap means that while nutritional deficiency prevalence is established in frailty cohorts, the mechanistic linkage to glycation pathways remains an inference rather than a directly tested hypothesis within the available data.

Population / prevalence remains a separate Results slice (n=1; claims=62; null signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Skeletal, Fracture, and Bone Outcomes

The thesis from Cavati 2023 posits that AGEs and oxidative stress are key mechanistic players in diabetes-associated bone fragility. The study's contribution lies in framing this relationship for fracture risk stratification, though it provides an effect direction classified as null in the curated corpus. This null finding suggests that while the mechanistic hypothesis is plausible, the direct, independent association between glycation and fracture risk in this specific cohort may be attenuated or confounded by other diabetic complications. The absence of reported p-values in the curated source means the statistical robustness of this null signal cannot be independently verified from the provided data. The evidence therefore points to a complex interplay where glycation's role in bone health is context-dependent. Further research with clear longitudinal fracture endpoints is needed to quantify this risk.

Mechanistically, the glycation hypothesis for bone fragility is coherent. AGEs are known to accumulate in collagen-rich tissues like bone, altering cross-linking and reducing material toughness. In a clinical context, this biochemical alteration could contribute to the increased fracture risk observed in diabetic patients independent of bone mineral density. The mechanistic substrate underlying this functional finding is the modification of the bone matrix's organic component. However, the current observational evidence from Cavati 2023 does not translate this plausible mechanism into a strong, independent epidemiological signal for fracture prediction. This gap between biological plausibility and clinical outcome underscores the need for intervention studies targeting AGE reduction.

A key tension within this single-study corpus is the disconnect between the proposed mechanistic role of AGEs in bone biology and the null clinical finding for fracture risk stratification. Cavati 2023 explicitly implicates glycation in the pathology of diabetic bone disease, yet the curated evidence classifies its effect direction as null. This disagreement highlights a common challenge in translational research: a pathway validated in preclinical models may not yield a detectable, independent signal in complex human cohorts burdened by comorbidities. The study's design as an observational cohort cannot establish causality, leaving the question of AGEs as a modifiable fracture risk factor unresolved. Future investigations must reconcile this by employing more direct measures of tissue-level glycation alongside prospective fracture adjudication.

Cross-Domain Synthesis

A fundamental tension emerges between the strong epidemiological and mechanistic association of advanced glycation end-products (AGEs) with cardiovascular disease and mortality, and the near-complete absence of clinical trial evidence demonstrating that reducing AGEs translates into improved hard outcomes. Furthermore, the observational data from Wu 2025 indicates a mixed but significant association between the hemoglobin glycation index—a marker of inter-individual glycation variability—and all-cause mortality in critically ill patients with atrial fibrillation, with multiple p-values below 0.001. However, when we turn to interventional evidence, the results are null. The RCT by Movahedian 2025, which administered 5 mg of melatonin for 10 weeks to peritoneal dialysis patients, found no significant effects on AGE levels or related cardiometabolic endpoints despite reporting several p-values below 0.05 for other markers. Similarly, the RCT by Ozdemir 2025 directly comparing a low-AGEs diet to a standard diet in PCOS patients observed similar weight loss and a negative or null effect on most metabolic and hormonal profiles, with critical p-values like 0.183 and 0.364 indicating no difference. The mechanistic plausibility, supported by preclinical and observational work suggesting AGEs drive vascular stiffness and inflammation (Vazquez-Agra 2025; Ustkoyuncu 2025), has not yet been successfully translated into a therapeutic strategy that modifies clinical endpoints. The boundary condition likely relates to the intervention type, dose, and duration; targeting the AGE-RAGE axis may require more specific inhibitors or longer-term dietary interventions than those tested. Resolving this tension requires long-term, adequately powered RCTs using AGE-lowering interventions with hard cardiovascular and mortality endpoints, rather than relying on the currently sparse and mechanistic-focused trial data.

The evidence base presents a stark conflict between the contextual and observational studies that consistently link dietary AGEs (dAGEs) intake to disease markers, and systematic reviews that find no clear association with cancer risk and mortality. This aligns with the mechanistic understanding that exogenous AGEs from cooking methods (Wellens 2025) contribute to the body's AGE pool and oxidative stress (Nowotny 2015). This null finding for a hard outcome like cancer mortality stands in opposition to the suggestive positive signal from Sukon 2024, where decreased SAF was associated with active ocular inflammation (OR not provided, but P = 0.04). The disagreement may stem from differences in measurement: observational studies often rely on food frequency questionnaires to estimate dAGEs intake, which is a surrogate endpoint for actual tissue AGE burden (Ioannidis 2005). In contrast, SAF directly measures tissue accumulation. The systematic review's null finding on cancer could indicate that dAGEs intake, as estimated from diet, is too imprecise a measure, or that its contribution to cancer risk is minor compared to other factors. The boundary condition is the precision of the exposure metric. Evidence that would resolve this includes prospective studies that simultaneously measure habitual dAGEs intake via validated biomarkers like urinary AGE excretion and track site-specific cancer incidence over decades.

A significant cross-domain tension exists between the evidence supporting AGEs as a biomarker of frailty, immune dysfunction, and accelerated aging, and the intervention data suggesting that reducing AGEs may not improve functional or inflammatory endpoints in older populations. The frailty context is rich with correlational data: Dahlen 2025 links fatigue and vitamin D status in frail elderly, a context where AGE accumulation is implicated, and Feitosa 2024 connects soluble RAGE (a decoy receptor for AGEs) with kidney function decline, a hallmark of aging. The immune system data is more direct; Sukon 2024 reports an association between SAF and active uveitis (P = 0.04), and Lee 2026 explores the anti-inflammatory potential of compounds against glyoxal-derived AGEs in a skin inflammation model. This suggests a clear pathway where AGEs modulate immune activation. However, the intervention evidence does not support a simple causal model. The RCT by Movahedian 2025, which aimed to reduce oxidative stress and inflammation in a high-risk, likely frail population (peritoneal dialysis patients), found no significant effect. Furthermore, the systematic review by Detopoulou 2024 on dietary AGE restriction in diabetes—a comorbidity strongly linked to frailty—yields an unclear effect direction, suggesting benefits are not straightforward. The tension here is between AGEs as a passive indicator of cumulative damage and immune dysregulation, and as an active therapeutic target. The boundary condition may be the irreversibility of AGE-mediated crosslinks; while AGE formation can be slowed, existing crosslinks in tissues like collagen may be permanent, limiting the efficacy of short-term interventions.

The corpus reveals a critical divergence in the hemoglobin glycation index (HGI) literature, where the same biomarker is associated with both increased and decreased mortality depending on the specific critical illness studied, creating a tension between a universal risk marker and a disease-context-specific signal. This aligns with the general premise that aberrant glycation is pathological. This is a direct contradiction. The mechanism underlying this paradox may involve the role of glucose availability and glycation in acute versus chronic stress responses, or fundamental pathophysiological differences between cerebrovascular, cardiac, and systemic inflammatory crises. The HGI is not measuring total AGE load but rather individual variation in the glycation of hemoglobin, which may reflect underlying metabolic flexibility or insulin dynamics. The boundary condition is therefore the specific disease state and the acuity of illness. For conditions like atrial fibrillation, hyperglycemia and glycation may indicate decompensation, whereas in hemorrhagic stroke, it might represent a necessary metabolic or neuroprotective response. Resolving this requires mechanistic studies in model organisms that mimic these specific disease states to understand the dual role of glycation under different pathophysiological pressures.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 45 curated reference papers, the evidence base for Glycation AGEs shows a context-dependent profile. Positive signals appear in: longevity, immune inflammation. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Glycation AGEs anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 45 included sources. The evidence-tier distribution is: B2 (n=40), B1 (n=3), A1 (n=2). By directness, the breakdown is: indirect (n=28), review (n=15), direct (n=2). 24 of 45 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct clinical trials, indirect clinical evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: older adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by observational cohorts and narrative reviews rather than randomized controlled trials designed to test causal AGE-reduction hypotheses on hard clinical endpoints. The remaining evidence base relies on cross-sectional associations, retrospective database analyses (e.g., Wu 2025, Zeng 2026, Lyu 2026 drawing from MIMIC-IV cohorts), and mechanistic reviews that cannot establish temporal sequence or dose-response causality. No long-term mortality RCT targeting AGE reduction in the general adult population was identified in this corpus. The absence of dedicated intervention trials with follow-up exceeding 12 months creates a gap that mechanistic plausibility alone cannot bridge.

External validity is constrained by narrow and demographically skewed enrollment across the included trials and cohorts. Movahedian 2025 enrolled exclusively peritoneal dialysis patients, a population whose uremic milieu accelerates AGE formation and whose pharmacokinetic environment differs fundamentally from the general adult population. Ozdemir 2025 recruited overweight women with polycystic ovary syndrome, a metabolically distinct phenotype characterized by insulin resistance and hyperandrogenism that limits generalizability to men, lean individuals, or other endocrine conditions. The collective enrollment profile means that the synthesis's conclusions apply most confidently to metabolically compromised middle-aged adults in clinical settings, not to broad population-level aging trajectories.

The endpoint scope of this corpus is heavily weighted toward surrogate and intermediate markers rather than validated hard clinical endpoints. Skin autofluorescence (SAF), the most frequently used AGE biomarker in the included studies, measures tissue AGE accumulation non-invasively but has not been formally qualified as a surrogate endpoint for cardiovascular events or mortality in regulatory frameworks; its predictive value for such outcomes remains associative (Ioannidis 2005). The skin-aging studies (Chang 2025, Dai 2025, Nukaly 2026, Luo 2026) relied on subjective wrinkle scores, hydration measurements, or skin tone assessments — outcomes that are clinically meaningful in dermatology but do not map directly to systemic aging biomarkers or lifespan. No study in this corpus measured AGE accumulation in relation to validated composite endpoints such as MACE (major adverse cardiovascular events), time-to-fracture, or all-cause mortality as a pre-specified primary outcome with adequate power. The Detopoulou 2024 systematic review of dietary AGE restriction RCTs in diabetes noted heterogeneity in outcome reporting across trials, further limiting the ability to pool hard endpoints. Consequently, the synthesis cannot determine whether AGE reduction translates to fewer cardiovascular events, fewer fractures, or prolonged survival based on the available evidence.

A substantial portion of the evidence base rests at the mechanistic or pre-clinical level, creating a translational gap between AGE biochemistry and demonstrated clinical benefit. Lee 2026 demonstrated that glyoxal-derived AGEs induce skin inflammation in a model system and that aloe vera flower extracts attenuate this response — but this is a cell-culture finding, not a clinical trial outcome. Xu 2023's systematic review of AGE effects on stem cell differentiation potential compiled in vitro data showing that AGEs impair osteogenic and adipogenic pathways, yet no corresponding clinical trial in this corpus tested whether AGE reduction preserves bone density or prevents fracture in humans. The Twarda-Clapa 2022 and Zhang 2025 reviews catalogued AGE receptor biology (RAGE, sRAGE, AGE-R1/R2/R3) and downstream NF-κB signaling, but the only clinical measurement of sRAGE in the corpus comes from Wong 2026's pediatric ARDS validation study and Feitosa 2024's genomic pleiotropy analysis — neither of which tested a therapeutic intervention. The mechanism-to-clinic gap is therefore wide: the corpus provides strong molecular rationale for AGEs as pathogenic mediators of vascular stiffening, renal decline, skin aging, and immune activation, yet the interventional evidence that blocking or reducing AGEs would reverse these processes in clinical practice is essentially absent from the curated references. Bridging this gap will require adequately powered RCTs with hard endpoints — trials that, at present, do not exist in this evidence base.

Conclusion

For glycation ages, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support glycation ages as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 45 included sources on Glycation AGEs across 10 outcome classes and 260 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

The strongest unresolved contrast is the disagreement between Intrapartum 2026 and Wu 2025 on longevity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Li 2026, Detopoulou 2024, Intrapartum 2026) emphasize convergent signals on Glycation AGEs. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	5	mixed, null, positive	conflict-resolution gap
muscle function	0	1	null	direct clinical gap
immune	0	1	null	direct clinical gap
cardiometabolic	2	4	negative, null, unclear	replication gap
contextual adjacent evidence	0	22	negative, null, unclear	direct clinical gap
immune and inflammation	0	2	null, positive	direct clinical gap
deficiency prevalence	0	1	null	direct clinical gap
mortality and survival	0	2	unclear	direct clinical gap
safety and comorbidity	0	4	null	direct clinical gap
skeletal, fracture, and bone	0	1	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: conflict-resolution gap	0 direct and 5 indirect sources; direction profile: mixed, null, positive
P2	muscle function: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P3	immune: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P4	cardiometabolic: replication gap	2 direct and 4 indirect sources; direction profile: negative, null, unclear
P5	contextual adjacent evidence: direct clinical gap	0 direct and 22 indirect sources; direction profile: negative, null, unclear

Next-Study Design Recommendation

The next high-yield study for Glycation AGEs should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Movahedian 2025; RCT (clinical); tier=A1; directness=direct; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.001.
• Ozdemir 2025; RCT (clinical); tier=A1; directness=direct; N=—; population=adults; endpoint=cardiometabolic; direction=negative; representative statistic=P = 0.001.
• Li 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=longevity; direction=null; representative statistic=P < 0.001.
• Detopoulou 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=contextual other; direction=unclear.
• Intrapartum 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=longevity; direction=null.
• Kopytek 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=negative; representative statistic=P < 0.0001.
• Chang 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.001.
• Wu 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=longevity; direction=mixed; representative statistic=P < 0.001.
• Dahlen 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=deficiency prevalence; direction=null; representative statistic=P < 0.001.
• Dai 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.001.

Load-Bearing Tensions

• Severity 4 disagreement: Intrapartum 2026 vs Wu 2025; Intrapartum 2026 (null) vs Wu 2025 (mixed) on longevity
• Severity 4 disagreement: Wu 2025 vs Wong 2026; Wu 2025 (mixed) vs Wong 2026 (null) on longevity
• Severity 4 disagreement: Wu 2025 vs Li 2026; Wu 2025 (mixed) vs Li 2026 (null) on longevity
• Severity 4 disagreement: Wu 2025 vs Zeng 2026; Wu 2025 (mixed) vs Zeng 2026 (positive) on longevity
• Severity 3 null vs positive: Intrapartum 2026 vs Zeng 2026; Intrapartum 2026 (null) vs Zeng 2026 (positive) on longevity
• Severity 3 null vs positive: Xu 2023 vs Detopoulou 2024; Xu 2023 (null) vs Detopoulou 2024 (unclear) on contextual other
• Severity 3 null vs positive: Xu 2023 vs Kopytek 2025; Xu 2023 (null) vs Kopytek 2025 (negative) on contextual other
• Severity 3 null vs positive: Xu 2023 vs Varoniukaite 2025; Xu 2023 (null) vs Varoniukaite 2025 (negative) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Alharbi 2026, Gao 2025, Azizzadeh 2026, Zhao 2025, Zhou 2025, Salmen 2025, Carmo 2025, Babtan 2026, Fenizia 2026, Stanescu 2026, Lee 2022, Stanescu 2025, Luevano-Contreras 2010, Studenski 2011, Tancredi 2015.

References

• Movahedian 2025. Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial. Scientific Reports, 2025. DOI: 10.1038/s41598-025-20792-2. PMID: 41125682.
• Kopytek 2025. Dysglycaemia is associated with the pattern of valvular calcification in micro-computed tomography analysis: an observational study in patients with severe aortic stenosis. Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02691-y. PMID: 40114166.
• Chang 2025. Novel Cyclized Hexapeptide‐9 Outperforms Retinol Against Skin Aging: A Randomized, Double‐Blinded, Active‐ and Vehicle‐Controlled Clinical Trial. Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.70290. PMID: 40586182.
• Wu 2025. Association of hemoglobin glycation index with all-cause mortality in critically ill patients with atrial fibrillation: a retrospective analysis from MIMIC-IV. BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-05089-6. PMID: 41469551.
• Li 2026. Differential impact of advanced glycation end-products on cardiovascular risk across patient populations measured by skin autofluorescence: a meta-analysis. European Journal of Medical Research, 2026. DOI: 10.1186/s40001-026-03912-0. PMID: 41588485.
• Dahlen 2025. Fatigue and Vitamin D Status in Frail Elderly with and without Cancer, and Healthy Controls of Different Ages: Results from the IMAGE Study. Gerontology, 2025. DOI: 10.1159/000548451. PMID: 40952957.
• Ozdemir 2025. Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial. Reproductive Sciences, 2025. DOI: 10.1007/s43032-025-01808-8. PMID: 39953370.
• Dai 2025. Dietary Supplement With Cherry Blossom Flower and Rosa roxburghii Tratt Fruit Extract Improves Skin Aging: A Randomized, Placebo‐Controlled, Blinded Clinical Study. Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.70536. PMID: 41215693.
• Wellens 2025. Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects. Cell Reports Medicine, 2025. DOI: 10.1016/j.xcrm.2025.102091. PMID: 40280130.
• Varoniukaite 2025. Association of Advanced Glycation End Products with Diabetic Retinopathy Severity in Lithuanian Patients. Medicina, 2025. DOI: 10.3390/medicina61111956. PMID: 41303793.
• Alharbi 2026. Dietary advanced glycation end products (AGEs) and type 2 diabetes (T2D): a case-control study. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1737974. PMID: 41717025.
• Wong 2026. Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome. BMJ Open Respiratory Research, 2026. DOI: 10.1136/bmjresp-2025-003630. PMID: 41494694.
• Vazquez-Agra 2025. Assessing the relationship between short-term blood pressure variability and glycation profile in young and middle-aged nondiabetic hypertensive individuals. Journal of Hypertension, 2025. DOI: 10.1097/HJH.0000000000004029. PMID: 40265460.
• Takagi 2026. Association of Corneal Biomechanical Properties with Fingertip-Measured Advanced Glycation End Products and Carotenoids in Glaucoma Patients. Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15020783. PMID: 41598720.
• Razak 2025. Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols, 2025. DOI: 10.2196/73039. PMID: 40986853.
• Gao 2025. Association between hemoglobin glycation index and myocardial infarction in critically ill patients with diabetes mellitus: a retrospective study based on MIMIC-IV. BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-04742-4. PMID: 40375098.
• Luo 2026. Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation for Improving Clinical Signs of Facial Skin Aging. Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70839. PMID: 41937110.
• Zeng 2026. Prognostic value of the hemoglobin glycation index in critically ill patients with hemorrhagic stroke: A retrospective cohort study using MIMIC-IV. Medicine, 2026. DOI: 10.1097/MD.0000000000048867. PMID: 42152413.
• Lyu 2026. Hemoglobin glycation index and mortality in chronic heart failure: A retrospective cohort study. Medicine, 2026. DOI: 10.1097/MD.0000000000046156. PMID: 41366976.
• Nukaly 2026. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1618306. PMID: 41924746.
• Sukon 2024. Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases. International Ophthalmology, 2024. DOI: 10.1007/s10792-024-02980-7. PMID: 38329659.
• Feitosa 2024. Discovery of genomic and transcriptomic pleiotropy between kidney function and soluble receptor for advanced glycation end products using correlated meta‐analyses: The Long Life Family Study. Aging Cell, 2024. DOI: 10.1111/acel.14261. PMID: 38932496.
• Ustkoyuncu 2025. Soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with obesity, insulin resistance and metabolic syndrome: A case-control study and the review of the literature. BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-02025-9. PMID: 40983915.
• Detopoulou 2024. Dietary Restriction of Advanced Glycation End-Products (AGEs) in Patients with Diabetes: A Systematic Review of Randomized Controlled Trials. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms252111407. PMID: 39518960.
• Azizzadeh 2026. Prevalence and determinants of vascular aging in Austria – a holistic view: the LEAD study. Journal of Hypertension, 2026. DOI: 10.1097/HJH.0000000000004227. PMID: 41537373.
• Cheng 2025. Efficacy and Safety of Topical Application of Plant‐Based Products on Skin Aging in Healthy Individuals: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.16710. PMID: 39654386.
• Zhao 2025. Exploration of brain imaging biomarkers in subthreshold depression patients across different ages: an ALE meta-analysis based on MRI studies. BMC Psychiatry, 2025. DOI: 10.1186/s12888-025-06495-y. PMID: 40033236.
• Zhou 2025. The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta‐Analysis. Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.16760. PMID: 39807700.
• Pascual-Morena 2025. Association of Dietary Advanced Glycation End Products with Overall and Site-Specific Cancer Risk and Mortality: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17101638. PMID: 40431378.
• Zhang 2025. Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants, 2025. DOI: 10.3390/antiox14040492. PMID: 40298887.
• Xu 2023. Effects of advanced glycation end products (AGEs) on the differentiation potential of primary stem cells: a systematic review. Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03324-5. PMID: 37038234.
• Salmen 2025. Could Skin Autofluorescence Be a Useful Biomarker in Systemic Lupus Erythematosus? A Systematic Review. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26146934. PMID: 40725181.
• Carmo 2025. Methylarginine levels and their impact on vascular aging: a systematic review. Vascular Biology, 2025. DOI: 10.1530/VB-25-0004. PMID: 41378901.
• Lee 2026. Exploring the Anti-Inflammatory Effects of Aloe vera Flower (AVF) and Its Active Ingredients in a Skin Inflammation Model Induced by Glyoxal-Derived Advanced Glycation End Products (GO-AGEs). Pharmaceuticals, 2026. DOI: 10.3390/ph19010121. PMID: 41599719.
• Babtan 2026. Correlation Between Advanced Glycation End Products and Ultrasonographic Measurements of Cervico-Facial Skin Tissue. Diagnostics, 2026. DOI: 10.3390/diagnostics16081206. PMID: 42072831.
• Fenizia 2026. Multimatrix Detection and Quantification of the Advanced Glycation End Products Precursor Fructoselysine via UHPLC-HRMS/MS. Metabolites, 2026. DOI: 10.3390/metabo16010078. PMID: 41590686.
• Stanescu 2026. Glutathione in Skin Aging and Tissue Regeneration: A Systematic Review of Molecular Mechanisms, Redox Modulation, and Biomedical Implications. Molecules, 2026. DOI: 10.3390/molecules31060981. PMID: 41900080.
• Lee 2022. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients, 2022. DOI: 10.3390/nu14153086. PMID: 35956261.
• Intrapartum 2026. Intrapartum Sildenafil in Laboring Mothers. 2026.
• Stanescu 2025. Skin Aging and Carotenoids: A Systematic Review of Their Multifaceted Protective Mechanisms. Nutrients, 2025. DOI: 10.3390/nu17162596. PMID: 40871623.
• Nowotny 2015. Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. Biomolecules, 2015. DOI: 10.3390/biom5010194. PMID: 25786107.
• Twarda-Clapa 2022. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells, 2022. DOI: 10.3390/cells11081312. PMID: 35455991.
• Cavati 2023. Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification. Antioxidants, 2023. DOI: 10.3390/antiox12040928. PMID: 37107303.
• Luevano-Contreras 2010. Dietary Advanced Glycation End Products and Aging. Nutrients, 2010. DOI: 10.3390/nu2121247. PMID: 22254007.
• Fotheringham 2022. Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?. Nutrients, 2022. DOI: 10.3390/nu14132675. PMID: 35807857.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Tancredi 2015. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.